WO2008135886A3 - Quinoline derivatives for use in the inhibition of the growth of tumour cells - Google Patents

Quinoline derivatives for use in the inhibition of the growth of tumour cells Download PDF

Info

Publication number
WO2008135886A3
WO2008135886A3 PCT/IB2008/051605 IB2008051605W WO2008135886A3 WO 2008135886 A3 WO2008135886 A3 WO 2008135886A3 IB 2008051605 W IB2008051605 W IB 2008051605W WO 2008135886 A3 WO2008135886 A3 WO 2008135886A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
growth
tumour cells
quinoline derivatives
halogen
Prior art date
Application number
PCT/IB2008/051605
Other languages
French (fr)
Other versions
WO2008135886A2 (en
Inventor
Constance Elizabeth Medlen
Kelly Chibale
De Melo Candice Soares
Original Assignee
Univ Pretoria
Constance Elizabeth Medlen
Kelly Chibale
De Melo Candice Soares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pretoria, Constance Elizabeth Medlen, Kelly Chibale, De Melo Candice Soares filed Critical Univ Pretoria
Publication of WO2008135886A2 publication Critical patent/WO2008135886A2/en
Publication of WO2008135886A3 publication Critical patent/WO2008135886A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides the use of a compound selected from compounds of the formula (2) and pharmaceutically acceptable salts thereof in which: R1 is halogen; either R2 is H and R3 is XR4 or R3 is H and R2 is XR4; X is -COCH=CH- or -CH=CHCO-; and XR4 is Formula (I) in which: R5, R6, R7, and R8 are independently H, halogen, OR9 or CH2- NR10R11 in which R9 is H or C1-C3 alkyl and R10 and R11 are together or independently H, pyrrolidinyl, piperidinyl, morpholinyl, -CH2 - morpholine, 1 -ethyl-1 -piperizinyl, t- butylamino, dimethylamino or diethylamino, in the manufacture of a medicament for the inhibition of the growth of tumour cells.
PCT/IB2008/051605 2007-05-02 2008-04-25 Quinoline derivatives for use in the inhibition of the growth of tumour cells WO2008135886A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200703521 2007-05-02
ZA2007/03521 2007-05-02

Publications (2)

Publication Number Publication Date
WO2008135886A2 WO2008135886A2 (en) 2008-11-13
WO2008135886A3 true WO2008135886A3 (en) 2009-03-19

Family

ID=39944078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/051605 WO2008135886A2 (en) 2007-05-02 2008-04-25 Quinoline derivatives for use in the inhibition of the growth of tumour cells

Country Status (1)

Country Link
WO (1) WO2008135886A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016006664A2 (en) * 2013-09-26 2017-08-01 Godavari Biorefineries Ltd compounds for inhibition of unregulated cell growth
WO2015063746A1 (en) * 2013-11-04 2015-05-07 The South African Nuclear Energy Corporation Limited Pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041811A1 (en) * 2002-11-02 2004-05-21 Astrazeneca Ab 3-cyano-quinoline derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041811A1 (en) * 2002-11-02 2004-05-21 Astrazeneca Ab 3-cyano-quinoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABADI ASHRAF H ET AL: "Synthesis and evaluation of novel 7-trifluoromethyl-4-(4-substituted anilino)quinolines as antiparasitic and antineoplastic agents.", ARZNEIMITTEL-FORSCHUNG 2003, vol. 53, no. 9, 2003, pages 655 - 663, XP001538678, ISSN: 0004-4172 *
KAMEL M M ET AL: "SOME REACTIONS WITH 4-P CINNAMOYLANILINOQUINOLINES", ZEITSCHRIFT FUER NATURFORSCHUNG. TEIL B, ANORGANISCHE CHEMIE,ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FUER NATURFORSCHUNG, TUEBINGEN, DE, vol. 40, no. 5, 1 January 1985 (1985-01-01), pages 661 - 663, XP009111199, ISSN: 0340-5087 *

Also Published As

Publication number Publication date
WO2008135886A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2009012418A (en) Quinazolin-oxime derivatives as hsp90 inhibitors.
CY1118879T1 (en) TRIAZINE COMPOUNDS AS P13 AND MTOR MODULAR INHIBITORS
MX2010005299A (en) Bis-(sulfonylamino) derivatives in therapy 066.
MX2009009238A (en) Novel phosphodi esterase inhibitors.
MX2009002010A (en) Heteroaryl derivatives as protein kinase inhibitors.
NO20090580L (en) Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
NO20091265L (en) Pyrrolopyrazine as Syk kinase inhibitor
TW200833675A (en) Nicotinamide derivatives
WO2009155121A3 (en) Inhibitors of pi3 kinase
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
PH12019502781A1 (en) Imidazole-containing inhibitors of alk2 kinase
MX2010008921A (en) Oxazolidinone derivatives.
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
MX2013003019A (en) Azabenzothiazole compounds, compositions and methods of use.
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP1854789A4 (en) Quinazoline derivative having tyrosine kinase inhibitory activity
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
NO20082112L (en) 3-Amino-2-arylpropylazaindoles and their use
TW200745063A (en) Triazolone derivatives
UA97256C2 (en) Substituted pyrazole and triazole compounds as ksp (kinesin spindle protein) inhibitors
TW200716547A (en) Piperidin-4-yl-amide derivatives
NO20092058L (en) Heteroaryl pyrrolidinyl ketone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751110

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751110

Country of ref document: EP

Kind code of ref document: A2